IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0172581.html
   My bibliography  Save this article

Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency

Author

Listed:
  • Louise Berendt
  • Lene Grejs Petersen
  • Karin Friis Bach
  • Henrik Enghusen Poulsen
  • Kim Dalhoff

Abstract

Objective: To characterize and quantify barriers towards the publication of academic drug trials. Study design: We identified academic drug trials approved during a 3-year period (2004–2007) by the Danish Medicines Agency. We conducted a survey among the trial sponsors to describe the rates of initiation, completion, and publication, and the reasons for the failure to reach each of these milestones. Information on size and methodological characteristics of the trials was extracted from the EudraCT database, a prospective register of all approved clinical drug trials submitted to European medicines agencies since 2004. Results: A total of 181 academic drug trials were eligible for inclusion, 139 of which participated in our survey (response rate: 77%). Follow-up time ranged from 5.1 to 7.9 years. Most trials were randomized controlled trials (73%, 95% CI 65–81%). Initiation and completion rates were 92% (95% CI: 88–97%) and 93% (95% CI: 89–97%) respectively. The publication rate of completed trials was 73% (95% CI: 62–79%). RCTs were published faster than non-RCTs (quartile time to publication 2.9 vs. 3.1 years, p = 0.0412). Conclusions: Many academic drug trials are left unpublished. Main barriers towards publication were related to the process from completion to publication. Hence, there is much to gain by facilitating the process from analysis to publication. Research institutions and funders should actively influence this process, e.g. by requiring the publication of trial results within a given time after completion.

Suggested Citation

  • Louise Berendt & Lene Grejs Petersen & Karin Friis Bach & Henrik Enghusen Poulsen & Kim Dalhoff, 2017. "Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-13, May.
    • Handle: RePEc:plo:pone00:0172581
    DOI: 10.1371/journal.pone.0172581
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0172581
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0172581&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0172581?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0172581. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.